Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that management will present a corporate overview and participate in one-on-one investor meetings at the HC Wainwright 23rd Annual Global Investment Conference. The company's presentation will be available on-demand beginning on Monday, September 13 at 7:00am EST.

Eledon Pharmaceuticals to Present at Two Investor Conferences in September

ReWalk Robotics

There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can get a huge return out of these stocks after the market has reassessed the share prices to near or above the liquidation value.

A Duo of Net Current Asset Value Stock Picks to Consider

Eledon Pharmaceuticals (ELDN) CEO David-Alexandre Gros on Q2 2021 Results - Earnings Call Transcript

Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022

Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021

Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501

Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transplantation

IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced the appointment of Jan Hillson, M.D., to the company's Board of Directors. Dr. Hillson currently serves as Senior Vice President of Clinical Development at Alpine Immune Sciences, a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases.

Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors

IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that management will present a corporate overview at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13 th at 2:00 pm EST.

Eledon Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

IRVINE, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30pm EST.

Eledon Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference

Eledon Pharmaceuticals (ELDN) CEO David-Alexandre Gros on Q1 2021 Results - Earnings Call Transcript

Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS)

Eledon Pharmaceuticals Reports First Quarter 2021 Operating and Financial Results

IRVINE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), announced upcoming presentations covering AT-1501, its lead product candidate, at the American Transplant Congress (ATC), which is being held virtually from June 4-9, 2021.   Accepted oral presentations include Phase 1 data on the safety, tolerability and pharmacokinetics of AT -1501, and pre-clinical data showing the effectiveness of AT-1501 in preventing islet allograft rejection in nonhuman primate models.   In addition, two posters will report on pre-clinical pharmacokinetics, toxicity, and characterization of AT-1501 binding and Fc effector function.

Eledon Pharmaceuticals Announces Upcoming Presentations on AT-1501 at the Virtual 2021 American Transplant Congress

Eledon Pharmaceuticals to Release First Quarter Financial Results on Thursday, May 13, 2021

As part of ongoing discussions with the FDA regarding Eledon Pharmaceuticals Inc's (NASDAQ: ELDN) AT-1501 renal transplant program, the agency has requested AT-1501 specific renal transplant data in non-human primates before starting a Phase 2 trial in renal transplantation in the U.S. Hence, Eledon plans to initiate an evaluation of AT-1501 in a standard non-human primate model of renal transplantation, which is expected to be completed by late 2022.

Eledon Pharma Stock Jumps Despite FDA Asking For Additional Preclinical Study In Non-Primate Animal Models

IRVINE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced an updated development strategy for AT-1501 in renal transplantation.

Eledon Pharmaceuticals Announces Update on Development Strategy for AT-1501 in Renal Transplantation

Eledon Pharmaceuticals (ELDN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Eledon Pharma (ELDN)

David Hovland, Ph.D., to serve as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer David Hovland, Ph.D., to serve as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer

Eledon Pharmaceuticals Continues to Bolster Leadership Team with Addition of Two More Key Executives

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Operating and Financial Results

Eledon Pharmaceuticals to Release Fourth Quarter and Full-Year Financial Results on Tuesday, March 30

News for Eledon Pharmaceuticals Stock (ELDN)